Thursday, December 8, 2022, 7:00 PM – 9:00 PM Central Time (8:00 PM – 10:00 PM Eastern Time) – San Antonio, Texas

What Clinicians Want to Know: Addressing Current Questions and Controversies in the Management of ER-Positive Breast Cancer (Part 2 of a 2-Part Series)

A CME Satellite Symposium Held in Conjunction with the 2022 San Antonio Breast Cancer Symposium®

Location
San Antonio Marriott Rivercenter
101 Bowie St
San Antonio, TX 78205
Hotel Phone: (210) 223-1000

Program Schedule — Central Time
6:30 PM – 7:00 PM — Registration and Dinner
7:00 PM – 9:00 PM — Educational Meeting

Meeting Room
To be announced


This event will also be webcast live.
Please see Registration tab for details.
There is no registration fee for this event. For the in-person symposium in San Antonio, preregistration is required as seating is limited.  
 
Faculty
Aditya Bardia, MD, MPH
Director, Breast Cancer Research Program
Associate Professor
Harvard Medical School
Attending Physician
Massachusetts General Hospital
Boston, Massachusetts

Matthew P Goetz, MD
Erivan K Haub Family Professor of Cancer Research Honoring Richard F Emslander, MD
Professor of Oncology and Pharmacology
Director, Mayo Clinic Breast SPORE
Co-Leader, Women’s Cancer Program
Chair, Breast Cancer Research Committee
Vice Chair, Academic and Community Research United (ACCRU)
Mayo Clinic
Rochester, Minnesota

Kevin Kalinsky, MD, MS
Associate Professor
Department of Hematology and Medical Oncology
Emory University School of Medicine
Director, Glenn Family Breast Center
Director, Breast Medical Oncology
Winship Cancer Institute of Emory University
Atlanta, Georgia


Virginia Kaklamani, MD, DSc
Professor of Medicine
Ruth McLean Bowman Bowers Chair in Breast Cancer Research and Treatment
AB Alexander Distinguished Chair in Oncology
Associate Director for Clinical Research
Leader of the Breast Cancer Program
UT Health San Antonio
The University of Texas
MD Anderson Cancer Center
San Antonio, Texas

Hope S Rugo, MD
Professor of Medicine
Director, Breast Oncology and Clinical Trials Education
University of California, San Francisco
Helen Diller Family Comprehensive Cancer Center
San Francisco, California

Moderator
Neil Love, MD
Research To Practice
Miami, Florida


This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Exact Sciences Corporation, Lilly, Novartis, Sanofi Genzyme, and TerSera Therapeutics LLC.
Program Schedule — Central Time
6:30 PM – 7:00 PM — Registration and Dinner Buffet
7:00 PM – 9:00 PM — Educational Meeting

MODULE 1: Current Role of Biomarker Analysis and Genomic Assays for Hormone Receptor (HR)-Positive Localized Breast Cancer

  • Current indications and optimal platforms for biomarker assessment (eg, Ki67, BRCA) in patients with newly diagnosed HR-positive localized breast cancer
  • Clinicopathologic factors affecting the risk of recurrence and the decision to consult a genomic classifier for ER-positive localized breast cancer
  • Design, eligibility criteria and major clinical findings from the Phase III RxPONDER trial evaluating the role of chemotherapy for patients with ER-positive, HER2-negative localized breast cancer with 1 to 3 positive lymph nodes and a 21-gene Recurrence Score® (RS) of ≤25
  • Benefit associated with chemotherapy for premenopausal versus postmenopausal patients in the RxPONDER trial; current role of the 21-gene RS for premenopausal patients with node-positive disease
  • Development, validation and utility of the RSClin educational tool integrating the 21-gene RS and clinicopathologic features to individualize treatment for localized ER-positive, node-negative disease
  • Available data sets with and current clinical utility of other genomic assays (eg, MammaPrint®, Prosigna®, Breast Cancer Index®, EndoPredict®) for ER-positive localized breast cancer

MODULE 2: Optimizing the Management of Localized ER-Positive Breast Cancer

  • Optimal selection and duration of adjuvant therapy for premenopausal and postmenopausal patients with ER-positive, HER2-negative localized breast cancer
  • Biologic rationale for the evaluation of CDK4/6 inhibitors for ER-positive, HER2-negative localized breast cancer
  • Key efficacy findings from the Phase III monarchE trial evaluating the addition of abemaciclib to standard adjuvant hormonal therapy for patients with ER-positive, HER2-negative breast cancer at high risk for recurrence
  • Spectrum, frequency and severity of toxicities reported with abemaciclib in the monarchE trial; rates of treatment discontinuation before 2 years
  • Indications for abemaciclib in localized breast cancer; patient selection and optimal utilization of adjuvant abemaciclib in clinical practice
  • Other ongoing studies (eg, NATALEE) evaluating CDK4/6 inhibitors as adjuvant or neoadjuvant therapy for ER-positive localized breast cancer
  • Efficacy and safety findings with olaparib as adjuvant therapy for patients with HR-positive localized breast cancer with BRCA mutations; current role of adjuvant olaparib

MODULE 3: Selection and Sequencing of Therapy for Patients with ER-Positive Metastatic Breast Cancer (mBC)

  • Long-term follow-up, including overall survival data, from pivotal clinical trials of palbociclib, ribociclib and abemaciclib for premenopausal and postmenopausal patients
  • Incidence, monitoring and management of commonly occurring and agent-specific toxicities associated with CDK4/6 inhibition (eg, cytopenias, gastrointestinal events, interstitial lung disease/pneumonitis and venous thromboembolic events)
  • Ongoing clinical trials (eg, HARMONIA, PACE, MAINTAIN) attempting to further define the role CDK4/6 inhibitors in therapy for ER-positive mBC
  • Mechanisms of resistance to CDK4/6 inhibition; prevalence, identification and prognostic significance of PIK3CA mutations in patients with ER-positive mBC
  • Available research findings with alpelisib-based treatment for patients with ER-positive mBC with a PIK3CA mutation, including those experiencing disease progression on a CDK4/6 inhibitor; optimal incorporation into current management algorithms
  • Spectrum, frequency and severity of alpelisib-related toxicities; optimal prevention and management strategies

MODULE 4: Novel Strategies Under Investigation for Patients with HR-Positive mBC

  • Biologic rationale for targeting TROP2 in patients with HR-positive mBC
  • Design, eligibility criteria and key efficacy and safety endpoints from the Phase III TROPiCS-02 trial evaluating sacituzumab govitecan in the treatment of HR-positive/HER2-negative mBC
  • Mechanism of action of and available data with datopotamab deruxtecan (dato-DXd) for HR-positive, HER2-negative mBC
  • Rationale for and design of the ongoing Phase III TROPION-Breast01 trial comparing dato-DXd to investigator’s choice of chemotherapy for HR-positive, HER2-negative mBC treated with 1 or 2 prior lines of systemic chemotherapy
  • Published findings and ongoing research with selective estrogen receptor downregulators (eg, elacestrant, amcenestrant giredestrant, camizestrant); potential role in clinical practice
  • Clinical findings with and ongoing investigation of other novel agents and strategies for HR-positive mBC (eg, capivasertib, FGFR inhibitors, patritumab deruxtecan)

MODULE 5: Emerging Appreciation of HER2 Low as a Unique Subset of HR-Positive Breast Cancer

  • Incidence and clinicopathologic characteristics of HER2-low breast cancer; appropriate testing strategies to identify patients with HER2-low breast cancer
  • Current management approach for HR-positive, HER2-low breast cancer; available efficacy and safety data with established HER2-targeted agents (eg, trastuzumab, pertuzumab, trastuzumab emtansine) for HER2-low breast cancer
  • Mechanism of action of trastuzumab deruxtecan (T-DXd); rationale for its activity in patients with HER2-low breast cancer
  • Published data with T-DXd for HER2-low mBC; effects of IHC status, HR status and prior therapy on outcomes
  • Design, eligibility criteria and key endpoints of the Phase III DESTINY-Breast04 study evaluating T‑DXd versus chemotherapy for previously treated HER2-low advanced breast cancer
  • Recently presented findings from the DESTINY-Breast04 trial demonstrating a significant improvement in progression-free survival and overall survival with T-DXd for HER2-low disease; implications for clinical practice
  • Design, eligibility criteria and key endpoints of the Phase III DESTINY-Breast06 trial assessing T-DXd versus physicians’ choice of chemotherapy for HR-positive, HER2-low mBC progressing after CDK4/6 inhibitor therapy

Target Audience
This activity is intended for medical oncologists, breast cancer surgeons, nurses, radiation oncologists and other healthcare professionals involved in the diagnosis and treatment of breast cancer.

Learning Objectives
Upon completion of this activity, participants should be able to

  • Evaluate the results of genomic assays and other relevant patient- and treatment-related factors to personalize adjuvant systemic therapy for newly diagnosed ER-positive, HER2-negative, lymph node-negative or node-positive breast cancer.
  • Comprehend available findings with CDK4/6 inhibitors for localized ER-positive, HER2-negative breast cancer, and assess the current role of these agents as a component of adjuvant treatment.
  • Individualize the selection and sequence of systemic therapy for patients with newly diagnosed ER-positive metastatic breast cancer (mBC), considering clinical presentation (eg, age, menopausal status, comorbidities, extent and sites of disease), prior treatment course (eg, de novo metastatic disease, type and duration of adjuvant therapy) and psychosocial status.
  • Appraise available research data with commercially available CDK4/6 inhibitors in the treatment ER-positive mBC, and optimally incorporate these agents into patient care.
  • Recognize the frequency of phosphoinositide-3 kinase (PI3K) pathway mutations in patients with ER-positive mBC, and employ evidence-based approaches to targeting these alterations in individuals with ER-positive, HER2-negative, PIK3CA-mutated disease.
  • Appreciate published efficacy and safety data with PARP inhibitors for patients with localized or metastatic breast cancer harboring BRCA1/2 mutations, and consider the diagnostic and therapeutic implications for nonresearch care.
  • Assess ongoing clinical studies evaluating novel agents and treatment strategies under development for ER-positive breast cancer, and counsel patients about the potential benefits of trial participation.

CME Credit Form
A CME credit form will be given to each participant at the conclusion of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Faculty disclosures to be provided.

Research To Practice CME Planning Committee Members, Staff and Reviewers — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Exact Sciences Corporation, Lilly, Novartis, Sanofi Genzyme, and TerSera Therapeutics LLC.

San Antonio Marriott Rivercenter
101 Bowie St
San Antonio, TX 78205
Hotel Phone: (210) 223-1000

Meeting Room
To be announced

Directions
The Marriott Rivercenter hotel is conveniently located within walking distance (1.5 blocks) of the Henry B González Convention Center where the 2022 San Antonio Breast Cancer Symposium is taking place.

 
This activity is intended for medical oncologists, breast cancer surgeons, nurses, radiation oncologists and other healthcare professionals involved in the diagnosis and treatment of breast cancer.

There is no fee to participate in this hybrid event. For the in-person symposium in San Antonio, preregistration is required as seating is limited.

​ Registration for this event is separate from the 2022 San Antonio Breast Cancer Symposium.
IN-PERSON registration for clinicians in practice/healthcare professionals

I am a practicing physician, fellow, nurse or other healthcare provider involved in the treatment of cancer.

In-Person Registration for clinicians in practice »
 
IN-PERSON registration for other/industry professionals*

Please note, a limited number of seats are currently available for nonclinicians on a first come, first served basis.

In-Person Registration for other/industry professionals »

* Individuals employed by for-profit organizations, including financial institutions, biotech or pharmaceutical companies
LIVE WEBCAST registration for all professionals

Please note, we will stream this event over Zoom. After registering you will receive a separate confirmation from Zoom with the viewing instructions.

REGISTRATION FOR WEBCAST »

Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating and meal service, please check in at our onsite registration desk 30 minutes before the start of the meeting. We cannot guarantee seating after the start of the program.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.

Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.